UK Biobank (core renewal)
Lead Research Organisation:
UK Biobank
Department Name: UNLISTED
Abstract
UK Biobank is supported by The Wellcome Trust, The National Institute of Health Research, The Medical Research Council, The British Heart Foundation and Cancer Research UK. The figures presented on this record represent the Medical Research Council funding contribution only with some additional UKRI Infrastructure funds in addition.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
Technical Summary
The UK Biobank resource has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. There are now sufficient numbers of incident cases of the commoner conditions to support extensive and powerful research into their determinants.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
Organisations
People |
ORCID iD |
Rory Collins (Principal Investigator) |
Publications
Cai H
(2023)
Graph Transformer Geometric Learning of Brain Networks Using Multimodal MR Images for Brain Age Estimation.
in IEEE transactions on medical imaging
Cai M
(2022)
Ambient Air Pollution Associated with Body Fat Percentages at Different Body Compartments: A Cohort Study of UK Biobank Participants.
in Environmental health perspectives
Cai M
(2021)
A unified framework for cross-population trait prediction by leveraging the genetic correlation of polygenic traits
in The American Journal of Human Genetics
Cai Y
(2018)
Road traffic noise, air pollution and incident cardiovascular disease: A joint analysis of the HUNT, EPIC-Oxford and UK Biobank cohorts.
in Environment international
Caleyachetty R
(2021)
United Kingdom Biobank (UK Biobank): JACC Focus Seminar 6/8.
in Journal of the American College of Cardiology
Calonge-Pascual S
(2023)
Self-perception of primary health-care staff about physical activity on prescription: A qualitative semi-structured interview.
in Semergen
Calvin CM
(2019)
Predicting incident dementia 3-8 years after brief cognitive tests in the UK Biobank prospective study of 500,000 people.
in Alzheimer's & dementia : the journal of the Alzheimer's Association
Calvin CM
(2022)
Association of Multimorbidity, Disease Clusters, and Modification by Genetic Factors With Risk of Dementia.
in JAMA network open
Calvin CM
(2019)
Sex-specific moderation by lifestyle and psychosocial factors on the genetic contributions to adiposity in 112,151 individuals from UK Biobank.
in Scientific reports
Camm CF
(2022)
Independent effects of adiposity measures on risk of atrial fibrillation in men and women: a study of 0.5 million individuals.
in International journal of epidemiology
Campbell C
(2022)
The role of common genetic variation in presumed monogenic epilepsies.
in EBioMedicine
Campbell D
(2022)
Effects of depression on employment and social outcomes: a Mendelian randomisation study.
in Journal of epidemiology and community health
Campbell DD
(2021)
Effects of increased body mass index on employment status: a Mendelian randomisation study.
in International journal of obesity (2005)
Campbell M
(2022)
Identification of 14 novel susceptibility loci for diaphragmatic hernia development and their biological and clinical implications: results from the UK Biobank.
in Surgical endoscopy
Campello VM
(2022)
Cardiac aging synthesis from cross-sectional data with conditional generative adversarial networks.
in Frontiers in cardiovascular medicine
Campos A
(2021)
Genetic Susceptibility to Pneumonia: A GWAS Meta-Analysis Between the UK Biobank and FinnGen
in Twin Research and Human Genetics
Campos AI
(2020)
Insights into the aetiology of snoring from observational and genetic investigations in the UK Biobank.
in Nature communications
Campos AI
(2020)
Genetic aetiology of self-harm ideation and behaviour.
in Scientific reports
Candès E
(2023)
Conformalized survival analysis
in Journal of the Royal Statistical Society Series B: Statistical Methodology
Canela-Xandri O
(2018)
An atlas of genetic associations in UK Biobank.
in Nature genetics
Canning J
(2022)
POS0576 ASSOCIATION BETWEEN POTENTIAL PROGNOSTIC FACTORS AND ADVERSE HEALTH OUTCOMES IN RHEUMATOID ARTHRITIS: A STUDY OF 5658 UK BIOBANK PARTICIPANTS
in Annals of the Rheumatic Diseases
Cannon S
(2023)
Recurrent 17q12 microduplications contribute to renal disease but not diabetes.
in Journal of medical genetics
Cao X
(2022)
Gene selection by incorporating genetic networks into case-control association studies.
in European journal of human genetics : EJHG
Cao X
(2022)
Life course traumas and cardiovascular disease-the mediating role of accelerated aging.
in Annals of the New York Academy of Sciences
Cao Z
(2023)
Causal association of leisure sedentary behavior with arthritis: A Mendelian randomization analysis.
in Seminars in arthritis and rheumatism
Cao Z
(2020)
Association of obesity status and metabolic syndrome with site-specific cancers: a population-based cohort study
in British Journal of Cancer
Cao Z
(2022)
Cortical profiles of numerous psychiatric disorders and normal development share a common pattern
in Molecular Psychiatry
Cao Z
(2021)
The Role of Healthy Lifestyle in Cancer Incidence and Temporal Transitions to Cardiometabolic Disease.
in JACC. CardioOncology
Cao Z
(2021)
Polygenic risk score, healthy lifestyles, and risk of incident depression.
in Translational psychiatry
Carreras-Torres R
(2018)
Role of obesity in smoking behaviour: Mendelian randomisation study in UK Biobank.
in BMJ (Clinical research ed.)
Carri?n-Castillo A
(2022)
The genetic architecture of cerebellar lobules: Insights from the UK Biobank
Carrion-Castillo A
(2020)
Genetic effects on planum temporale asymmetry and their limited relevance to neurodevelopmental disorders, intelligence or educational attainment.
in Cortex; a journal devoted to the study of the nervous system and behavior
Carruthers R
(2022)
Representational ethical model calibration.
in NPJ digital medicine
Carss KJ
(2020)
Spontaneous Coronary Artery Dissection: Insights on Rare Genetic Variation From Genome Sequencing.
in Circulation. Genomic and precision medicine
Carter A
(2022)
Correction to: Educational attainment as a modifier for the effect of polygenic scores for cardiovascular risk factors: cross-sectional and prospective analysis of UK Biobank
in International Journal of Epidemiology
Carter A
(2022)
Cross-sectional analysis of educational inequalities in primary prevention statin use in UK Biobank
in Heart
Carter JL
(2019)
Reproducibility of dietary intakes of macronutrients, specific food groups, and dietary patterns in 211 050 adults in the UK Biobank study.
in Journal of nutritional science
Description | Impact of clinically silent atrial fibrillation on cerebrovascular disease and cognitive decline in the UK Biobank Imaging Cohort |
Amount | £2,474,260 (GBP) |
Funding ID | RG/18/6/33576 |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2019 |
End | 06/2024 |
Description | UK Biobank - The Repeat Imaging Project |
Amount | £2,500,000 (GBP) |
Funding ID | R39738/CN039 |
Organisation | MRC Dementias Platform UK |
Sector | Academic/University |
Country | United Kingdom |
Start | 04/2019 |
End | 01/2023 |
Description | UK Biobank - Whole genome sequencing of 50,000 UKB participants |
Amount | £30,000,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2020 |
Description | UK Biobank- Expansion of the UKB imaging to a 4th centre and repeat imaging assessment of 10,000 participants |
Amount | £8,500,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 12/2022 |
Description | UK Biobank Scientific Conference |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | The UK Biobank Scientific Symposium included presentations about the successes and future plans of the UK Biobank. It took place on 21 June 2018 in London |
Year(s) Of Engagement Activity | 2018 |
Description | UK Biobank participant imaging event |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UK Biobank for participants of the imaging work |
Year(s) Of Engagement Activity | 2021 |
Description | UKBiobank participant events - 2014 - 2019 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UKB Biobank participants regularly attend events aimed at informing them about the work being undertaken with their data. Usually, the events last a few hours and include an overview from the chief scientist and two talks from scientists that have used UKB data. From 2014 - 2020 over 4,000 participants have taken part in events in Edinburgh (4), Manchester (4), Nottingham, Leeds, Cardiff (2), Newcastle (5), Glasgow (2), Bristol (2) and Reading(4). They are often over-subscribed and participants leave these events wishing to seek more information and support he programme in new ways (EG in imaging, genome sequencing) |
Year(s) Of Engagement Activity | 2014,2015,2016,2017,2018,2019 |
URL | http://www.ukbiobank.ac.uk |